OOIR: Observatory of International Research

Papers

(The H4-Index of Allergy is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Risk factors for severe and critically ill COVID‐19 patients: A review	974
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria	516
EAACI guidelines: Anaphylaxis (2021 update)	253
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update	196
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease	181
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice	155
The role of allergen‐specific IgE, IgG and IgA in allergic disease	140
Advances and highlights in allergic rhinitis	119
Interleukin‐31: The “itchy” cytokine in inflammation and therapy	113
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches	112
Abstracts Poster	112
Advances and highlights in biomarkers of allergic diseases	107
Spotlight on microRNAs in allergy and asthma	103
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?	102
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines	91
Advances and highlights in asthma in 2021	90
Biologics and airway remodeling in severe asthma	90
Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation	90
The global burden of illness of peanut allergy: A comprehensive literature review	90
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines	86
The ingenious mast cell: Contemporary insights into mast cell behavior and function	85
Regulatory B cells, A to Z	84
Predictors of treatment response in chronic spontaneous urticaria	83
Butyrate as a bioactive human milk protective component against food allergy	83
Frequency of food allergy in Europe: An updated systematic review and meta‐analysis	81

Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy	81
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 201	80
Climate change and global health: A call to more research and more action	77
Risk factors for severe reactions in food allergy: Rapid evidence review with meta‐analysis	76
Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: A systematic review and meta‐analysis	73
Advances and novel developments in mechanisms of allergic inflammation	73
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations	73
Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement	72
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients	71
Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity	70
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives	69
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis	69
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation	68
Update on pathomechanisms and treatments in allergic rhinitis	65
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma	64
Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19	64
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper	64
Cold urticaria – What we know and what we do not know	63
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion	63
Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19	63
World Health Organization global air quality guideline recommendations: Executive summary	62
The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study	60
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status	59
Abstracts	59
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper	59
Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort	58
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper	57
Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!	57
Hypersensitivity reactions to chemotherapy: an EAACI Position Paper	56
The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria	56
Role of dietary fiber in promoting immune health—An EAACI position paper	56